Why is GoodRx being investigated? The truth about prescription drug pricing

You might have seen the headlines. GoodRx is a digital health company known for its free prescription discount cards and price comparison tools. For years, it has been the go-to app for millions of Americans trying to figure out why their blood pressure medication costs $5 at one pharmacy and $40 at another. But recently, the spotlight shifted from helping patients save money to scrutinizing how the company makes its own profit. Federal regulators, state attorneys general, and even Congress are asking hard questions: Is this model actually lowering drug prices, or is it just moving money around while keeping costs high for everyone else?

If you rely on these discounts, you need to understand what’s happening. This isn’t just corporate gossip; it affects your wallet and your access to care. Let’s break down exactly why GoodRx is under investigation, what the allegations mean for real people, and where things stand as we move through 2026.

The Core Allegations: How Does GoodRx Make Money?

To understand the investigation, you first have to understand the business model. On the surface, GoodRx seems like a charity. You scan a barcode, show a QR code at the counter, and pay less. No insurance required. It feels like a hack. But nothing in healthcare is free.

GoodRx generates revenue primarily through two channels: advertising from pharmaceutical manufacturers and referral fees from pharmacies. When you use the GoodRx card, the pharmacy sells the drug at a discounted cash price. However, that price is often still higher than what the pharmacy paid for the drug (the wholesale acquisition cost). The difference-the margin-is split between the pharmacy and GoodRx. Additionally, pharma companies pay GoodRx to promote their drugs when they appear as the "best price" option in the app.

Pharmacy Benefit Managers (PBMs) are intermediaries that process prescription drug claims for health insurers, employers, and government programs. Traditional PBMs negotiate rebates with drugmakers in exchange for placing those drugs on preferred lists. GoodRx operates differently, bypassing traditional insurance networks entirely. Critics argue this creates a shadow market where transparency is low, and incentives are misaligned. The core allegation isn’t that GoodRx is stealing money directly from patients. It’s that the structure of its deals may violate anti-kickback statutes or create conflicts of interest that ultimately harm consumers by inflating list prices.

Federal Scrutiny: HHS OIG and Anti-Kickback Laws

The biggest hammer in the room comes from the federal government. The Department of Health and Human Services Office of Inspector General (HHS OIG) has been investigating whether GoodRx’s payments from pharmaceutical companies constitute illegal kickbacks. Under the Anti-Kickback Statute (AKS) is a federal law that prohibits offering, paying, soliciting, or receiving remuneration to induce referrals of items or services reimbursable by federal healthcare programs., it is illegal to exchange anything of value to induce referrals for services payable by Medicare or Medicaid.

Here is the tricky part: GoodRx cards can technically be used alongside Medicare Part D. If a patient uses a GoodRx discount instead of their insurance coverage, it can mess up their deductible calculations and potentially leave them paying more out-of-pocket in the long run. Regulators argue that if GoodRx is incentivized by pharma companies to push certain drugs, and those drugs are then purchased using federal funds (even indirectly), the entire chain might be tainted by illegal inducements.

In late 2024 and early 2025, multiple subpoenas were issued to GoodRx executives. The investigators want to see internal communications regarding how they select which drugs to feature prominently in the app. Did they choose the cheapest option for the patient, or the one that paid the highest advertising fee? That distinction is the heart of the legal battle.

State-Level Actions: California and New York Lead the Charge

While Washington D.C. debates federal statutes, individual states are taking matters into their own hands. State Attorneys General have broad powers to protect consumer interests within their borders. In 2025, a coalition led by the attorneys general of California and New York filed formal complaints against GoodRx.

Their argument focuses on deceptive trade practices. They claim that GoodRx markets itself as an unbiased tool for finding the lowest price, but fails to disclose that its rankings are influenced by commercial agreements. Imagine going to a restaurant guide that only lists restaurants that pay a commission, but doesn’t tell you that’s how they make money. That’s the analogy state prosecutors are using.

Furthermore, some states are investigating whether GoodRx’s discount cards violate specific state laws regarding the resale of prescription drugs. In jurisdictions with strict price-gouging protections, the markup GoodRx takes on certain medications is being challenged as unfair. These state cases are significant because they can result in immediate fines and forced changes to business practices, regardless of the outcome in federal court.

Impact on Patients: Why Should You Care?

This might sound like legal jargon, but it hits home fast. Here is how the investigation impacts you, the patient:

• Confusion at the Counter: Pharmacists are increasingly hesitant to accept third-party discount cards due to the regulatory uncertainty. Some chains have paused participation in certain rebate programs linked to GoodRx, leading to sudden spikes in cash prices for common generics.
• Medicare Deductible Risks: If you are on Medicare Part D, using a GoodRx card instead of your plan’s formulary can prevent the purchase from counting toward your true-out-of-pocket maximum. You might pay $10 today with GoodRx, but miss out on reaching the "catastrophic coverage" phase faster. Regulators warn that steering patients away from insurance benefits without clear disclosure is harmful.
• Price Volatility: As GoodRx adjusts its algorithms to comply with ongoing investigations, the prices you see in the app may fluctuate wildly. A drug that was $8 last month might jump to $25 next week if the promotional deal expires or is deemed non-compliant.

The goal of these investigations is not to shut down savings. It is to ensure that the savings are real, transparent, and not coming at the expense of the broader healthcare system’s integrity.

The Bigger Picture: Drug Pricing Reform in 2026

GoodRx is a symptom of a larger disease: the broken US drug pricing system. For decades, list prices for prescriptions have skyrocketed, while actual transaction prices remain opaque. Patients rarely know what a drug truly costs until they reach the pharmacy counter.

In 2026, the momentum for reform is stronger than ever. The Inflation Reduction Act, passed in previous years, gave Medicare the power to negotiate prices for certain high-cost drugs. This shifts the dynamic. If Medicare can negotiate better rates, the gap between insured and uninsured prices narrows. This puts pressure on companies like GoodRx, whose value proposition relies on the chaos of unregulated cash prices.

Congressional hearings in early 2026 featured testimony from former GoodRx employees who described internal pressures to prioritize revenue-generating partnerships over patient-centric pricing. While no criminal charges have been filed yet, the reputational damage is significant. Investors are nervous, and partners are re-evaluating contracts.

The investigation serves as a stress test for the entire industry. If GoodRx is found liable, it could set a precedent that forces all digital health platforms to disclose their financial relationships with pharma companies clearly. This would mean more transparency for you, but potentially fewer "free" apps offering deep discounts.

What Happens Next? Timeline and Expectations

Legal processes move slowly. As of mid-2026, here is where things stand:

1. Discovery Phase: GoodRx is currently producing thousands of documents related to its algorithmic ranking systems and payment structures. This process will likely continue through late 2026.
2. Settlement Talks: It is common for companies in this position to explore settlements. A settlement might involve paying fines and agreeing to change how they label sponsored content in the app. This could happen anytime in 2027.
3. Congressional Oversight: Expect new legislation proposed in 2027 that specifically targets "discount card intermediaries," requiring standardized disclosures and banning certain types of pharma-paid promotions.

For now, GoodRx remains operational. The app still works, and the discounts are still available. However, savvy patients are diversifying their strategies. Many are combining GoodRx with other tools like Cost Plus Drugs (Mark Cuban’s mail-order service) or direct negotiations with local independent pharmacies.

How to Protect Yourself While the Dust Settles

You don’t need to be a lawyer to navigate this. Here are practical steps to ensure you aren’t caught in the crossfire:

• Always Ask About Insurance First: Before swiping your GoodRx card, ask the pharmacist, "Will this count toward my deductible?" If the answer is no, calculate if the short-term savings outweigh the long-term cost of missing your catastrophic threshold.
• Compare Multiple Sources:: Don’t rely solely on one app. Check prices on GoodRx, RxSaver, and your insurer’s online portal. Prices can vary by $10-$20 for the same generic drug depending on the day and the specific pharmacy contract.
• Watch for Disclosures: Look closely at the fine print in the app. If a drug is marked as "Sponsored" or "Featured," assume the price might be inflated compared to a non-sponsored alternative. Scroll down to see the full list.
• Consider Mail-Order Options: For maintenance medications (like statins or birth control), look into 90-day supply options through mail-order pharmacies. These often have lower per-unit costs and less volatility than retail counter transactions.